|
Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Lilly; Merck Serono; Roche/Genentech |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |
|
|
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Pfizer; Takeda |
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; MSD; Novartis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Employment - Hospital Corporation of America |
Honoraria - BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck Serono; Novartis; SERVIER |
Consulting or Advisory Role - Merck Serono; SERVIER |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer |
|
|
Consulting or Advisory Role - Eisai; Pfizer |
Speakers' Bureau - Eisai; Ipsen; Lilly; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Daiichi Sankyo; Merck KGaA; Taiho Pharmaceutical; Takeda |
Research Funding - Otsuka |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Employment - Institut de Recherches Internationales Servier |
|
|
Employment - Institut de Recherches Internationales Servier |
|
|
|
Stock and Other Ownership Interests - Gerson Lehrman Group |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical |